TABLE 3.
Factors Associated With Death
| HR (95% CI) | P | aHR (95% CI) n = 932 | P | |
| Sex | ||||
| Female | Reference | __ | ||
| Male | 2.10 (1.57 to 2.81) | <0.001 | ||
| Age | ||||
| 18–29 | Reference | __ | Reference | __ |
| 30–44 | 2.68 (1.30 to 5.51) | 0.007 | 2.37 (0.98 to 5.75) | 0.056 |
| 45–59 | 4.73 (3.13 to 7.15) | <0.001 | 2.96 (1.44 to 6.08) | 0.003 |
| 60+ | 11.31 (5.32 to 24.06) | <0.001 | 8.86 (3.90 to 20.14) | <0.001 |
| ART reason | ||||
| Non-PMTCT | Reference | __ | Reference | __ |
| PMTCT | 0.17 (0.07 to 0.43) | <0.001 | 0.36 (0.15 to 0.87) | 0.022 |
| ART start yr | ||||
| 2014 | 1.29 (0.82 to 2.04) | 0.268 | ||
| 2015 | Reference | __ | ||
| 2016 | 1.20 (0.67 to 2.14) | 0.536 | ||
| 2017 | 1.28 (0.83 to 1.97) | 0.258 | ||
| Time on ART | ||||
| ≤3 mo | Reference | __ | Reference | __ |
| 3–6 mo | 0.56 (0.31 to 0.99) | 0.048 | 0.76 (0.46 to 1.25) | 0.276 |
| 6–12 mo | 0.74 (0.49 to 1.13) | 0.167 | 0.82 (0.56 to 1.20) | 0.307 |
| 12–24 mo | 0.53 (0.31 to 0.91) | 0.023 | 0.44 (0.23 to 0.85) | 0.015 |
| >24 mo | 0.91 (0.41 to 2.05) | 0.828 | 0.60 (0.23 to 1.56) | 0.297 |
| Baseline CD4 | ||||
| <100 | 4.26 (3.11 to 5.82) | <0.001 | 3.77 (2.31 to 6.15) | <0.001 |
| 100–199 | 2.57 (1.60 to 4.12) | <0.001 | 2.35 (1.49 to 3.69) | <0.001 |
| 200–349 | Reference | __ | Reference | __ |
| 350–499 | 0.78 (0.39 to 1.55) | 0.483 | 1.11 (0.53 to 2.36) | 0.776 |
| 500+ | 0.82 (0.24 to 2.79) | 0.756 | 1.13 (0.35 to 3.67) | 0.840 |
| Baseline WHO stage | ||||
| I | Reference | __ | Reference | __ |
| II | 1.71 (0.98 to 3.00) | 0.061 | 0.86 (0.40 to 1.86) | 0.706 |
| III | 2.70 (1.77 to 4.14) | <0.001 | 1.36 (0.94 to 1.96) | 0.102 |
| IV | 6.64 (3.08 to 14.32) | <0.001 | 3.14 (1.14 to 8.59) | 0.026 |
| Refill schedule | ||||
| 1 mo | Reference | __ | ||
| 2 mo | 0.83 (0.37 to 1.86) | 0.647 | ||
| 3 mo | 0.93 (0.49 to 1.75) | 0.824 | ||
| >3 mo | 0.74 (0.22 to 2.42) | 0.615 | ||
| Health facility | ||||
| Agincourt | Reference | __ | Reference | __ |
| Belfast | 1.03 (0.97 to 1.09) | 0.345 | 0.80 (0.61 to 1.05) | 0.108 |
| Cunningmore | 3.14 (2.98 to 3.31) | <0.001 | 3.39 (2.92 to 3.94) | <0.001 |
| Justicia | 2.10 (1.98 to 2.24) | <0.001 | 1.70 (1.55 to 1.86) | <0.001 |
| Kildare | 1.90 (1.84 to 1.95) | <0.001 | 1.08 (0.78 to 1.50) | 0.639 |
| Bhubezi | 1.26 (1.19 to 1.34) | <0.001 | 0.96 (0.73 to 1.28) | 0.810 |
| Thulamahashe | 0.93 (0.91 to 0.95) | <0.001 | 1.59 (1.15 to 2.22) | 0.005 |
| Xanthia | 1.75 (0.70 to 1.80) | <0.001 | 1.98 (1.64 to 2.38) | <0.001 |
| Time since last appointment | ||||
| ≤1 yr | Reference | __ | Reference | __ |
| 1–2 yrs | 1.57 (1.03 to 2.39) | 0.037 | 1.75 (1.10 to 2.78) | 0.018 |
| >2 yrs | 1.65 (0.73 to 3.75) | 0.228 | 0.81 (0.39 to 1.67) | 0.564 |
All CD4 data was retrieved from clinic records (files and TIER.Net). All other clinical data was retrieved from the PIRL database (sex and age were crosschecked in clinic and HDSS records).